Other revenue primarily includes revenue from non-core operations acquired in connection with the PLIVA acquisition, including the diagnostic, disinfectants, dialysis and infusions business. Other revenue totaled $45 million for calendar 2007 and $12 million for the fourth quarter of 2007.
Generic: Margins in the generic segment were 47% for both the quarter and year ended December 31, 2007.
Proprietary: Margins in the proprietary segment for the quarter and year ended December 31, 2007 were 55% and 68%, respectively. Proprietary margins for the fourth quarter ended December 31, 2007 were negatively impacted by a $13.7 million, or $0.08 per share, charge related to a product royalty contingency agreement for the Company's Cenestin(R) product.
Update on R&D Activities
Research and development investment for the quarter and year ended December 31, 2007 totaled $62 million and $248 million, respectively.
During 2007, the Company filed 30 Abbreviated New Drug Applications
(ANDAs), resulting in approximately 70 ANDAs, including tentatively
approved applications pending at the U.S. Food and Drug Administration
(FDA) at the end of the year. These ANDAs target branded pharmaceutical
products with an estimated $29 billion in annual sales. The Company also
filed 224 product registrations, representing 65 molecules with regulatory
bodies in Europe and in the ROW during 2007, resulting in 287 product
registrations, representing 90 molecules pending with regulatory bodies in
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved